Literature DB >> 18617296

Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.

Caroline L Trotter1, Jodie McVernon, Mary E Ramsay, Cynthia G Whitney, E Kim Mulholland, David Goldblatt, Joachim Hombach, Marie-Paule Kieny.   

Abstract

Conjugate vaccines exist that offer protection against disease caused by Haemophilus influenzae type b (Hib), and selected serogroups/serotypes of Neisseria meningitidis and Streptococcus pneumoniae. These vaccines are not only able to prevent serious disease, but they also provide protection against asymptomatic carriage. The resulting herd immunity effects have been striking, and have played an important role in the public health success of conjugate vaccination programmes. The aim of this paper is to review the state of the current evidence on conjugate vaccines and to identify important areas for further study, in order to inform the debate regarding the best use of these vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617296     DOI: 10.1016/j.vaccine.2008.05.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.

Authors:  Linxiao Chen; Jenny L Valentine; Chung-Jr Huang; Christine E Endicott; Tyler D Moeller; Jed A Rasmussen; Joshua R Fletcher; Joseph M Boll; Joseph A Rosenthal; Justyna Dobruchowska; Zhirui Wang; Christian Heiss; Parastoo Azadi; David Putnam; M Stephen Trent; Bradley D Jones; Matthew P DeLisa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-06       Impact factor: 11.205

Review 2.  The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality.

Authors:  Evropi Theodoratou; Sue Johnson; Arnoupe Jhass; Shabir A Madhi; Andrew Clark; Cynthia Boschi-Pinto; Sunil Bhopal; Igor Rudan; Harry Campbell
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

Review 3.  Delivering vaccines to the people who need them most.

Authors:  Michèle Anne Barocchi; Rino Rappuoli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

4.  Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.

Authors:  Brian L Cheng; Travis B Nielsen; Paul Pantapalangkoor; Fan Zhao; Jean C Lee; Christopher P Montgomery; Brian Luna; Brad Spellberg; Robert S Daum
Journal:  Hum Vaccin Immunother       Date:  2017-04-19       Impact factor: 3.452

Review 5.  Bacterial protein N-glycosylation: new perspectives and applications.

Authors:  Harald Nothaft; Christine M Szymanski
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

6.  Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.

Authors:  David Skurnik; Andrea Kropec; Damien Roux; Christian Theilacker; Johannes Huebner; Gerald B Pier
Journal:  Clin Infect Dis       Date:  2012-07-17       Impact factor: 9.079

7.  Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice.

Authors:  David Skurnik; Massimo Merighi; Martha Grout; Mihaela Gadjeva; Tomas Maira-Litran; Maria Ericsson; Donald A Goldmann; Susan S Huang; Rupak Datta; Jean C Lee; Gerald B Pier
Journal:  J Clin Invest       Date:  2010-08-25       Impact factor: 14.808

8.  Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Authors:  Marina L Gening; Tomás Maira-Litrán; Andrea Kropec; David Skurnik; Martha Grout; Yury E Tsvetkov; Nikolay E Nifantiev; Gerald B Pier
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

Review 9.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

10.  T cells control the generation of nanomolar-affinity anti-glycan antibodies.

Authors:  Zinaida Polonskaya; Shenglou Deng; Anita Sarkar; Lisa Kain; Marta Comellas-Aragones; Craig S McKay; Katarzyna Kaczanowska; Marie Holt; Ryan McBride; Valle Palomo; Kevin M Self; Seth Taylor; Adriana Irimia; Sanjay R Mehta; Jennifer M Dan; Matthew Brigger; Shane Crotty; Stephen P Schoenberger; James C Paulson; Ian A Wilson; Paul B Savage; M G Finn; Luc Teyton
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.